Business Context and Reporting Period
Company: BioLife Solutions, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2009
Business Overview: The Company develops, manufactures, and markets patented hypothermic storage and cryopreservation solutions (HypoThermosol, CryoStor, BloodStor) for cells, tissues, and organs. It also provides contracted R&D and consulting services.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2009 | Nine Months Ended Sep 30, 2009 |
|---|---|---|
| Total Revenue | $447,360 | $1,101,000 |
| Gross Profit | $117,815 | $322,327 |
| Gross Margin | 26% | 29% |
| Operating Loss | $(432,885) | $(2,057,015) |
| Net Loss | $(562,621) | $(2,413,118) |
| Cash and Cash Equivalents | $95,814 (as of Sep 30, 2009) | N/A |
| Net Cash Used in Operating Activities | N/A | $(2,155,160) |
| Total Debt (Related Party Notes) | $7,588,127 (Current) | N/A |
| Accumulated Deficit | $(49,855,987) | N/A |
Material Changes vs. Prior Period
- Revenue Growth: Product sales increased 49% ($144,906) for the three months and 24% ($211,283) for the nine months compared to 2008, driven by new customers and the launch of BloodStor.
- Margin Compression: Gross margins declined significantly from 57% to 26% (three months) and 42% to 29% (nine months). This is attributed to the transition from contract manufacturing to internal manufacturing in May 2009, resulting in lower factory utilization during the start-up phase.
- Expense Fluctuations:
- R&D: Decreased 22% in the quarter due to workforce reductions, but increased 13% year-to-date due to lab build-out costs.
- Sales & Marketing: Increased 64% in the quarter and 85% year-to-date due to new hires and trade show expenses.
- G&A: Decreased 28% in the quarter and 19% year-to-date, primarily due to reduced legal fees.
- Debt Increase: The Company drew an additional $2,525,000 on related-party loan facilities during the nine months, bringing the total principal balance to $7,588,127.
Outlook, Risks, and Management Commentary
- Going Concern: The filing explicitly states substantial doubt about the Company's ability to continue as a going concern due to an accumulated deficit of approximately $50 million and inability to generate sufficient operating income.
- Liquidity Strategy: Operations are funded primarily by Secured Convertible Multi-Draw Term Loan Facilities from related parties (Thomas Girschweiler and Walter Villiger). The Company has $1,411,873 remaining to draw on these facilities.
- Debt Maturity: The loan facilities are due January 11, 2010. Management is in discussions to extend the repayment date until the Company becomes cash flow positive or raises additional capital.
- Capital Needs: The Company expects to need additional capital to reach sustainable positive cash flow. There is no assurance that current investors will extend terms or that new capital will be available without dilution.
- Manufacturing Transition: Management anticipates gross margins will improve in future periods as internal manufacturing utilization increases.
Investor Verification Checklist
- Debt Extension: Verify if the related-party lenders have agreed to extend the January 11, 2010 repayment deadline.
- Cash Runway: Assess if the remaining $1.4 million in loan availability and current cash ($95,814) are sufficient to cover operating losses until profitability is achieved.
- Margin Recovery: Monitor future quarters to confirm if gross margins improve as internal manufacturing scales up.
- Dilution Risk: Evaluate the terms of the convertible notes (conversion at 85% of financing price) and potential dilution in any future equity financing.
- Legal Contingencies: Review the status of current litigation mentioned as a risk factor for adverse financial outcomes.